Loading
EP4 is one of the receptors for prostaglandin E2, a signal many tumours release that quietens the immune cells around them. EP4 blockers are meant to lift that suppression, and two are in early trials, one with pembrolizumab. This dossier gathers the 1 product (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
G protein-coupled receptor for prostaglandin E2 coupled to G(s) and cyclic AMP (UniProt P35408).
| Modality | Phase 1 |
|---|---|
| Small molecule 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 1 | Recruiting | A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"EP4" OR ABSTRACT:"EP4" OR TITLE:"PTGER4" OR ABSTRACT:"PTGER4" OR TITLE:"prostaglandin E receptor 4" OR ABSTRACT:"prostaglandin E receptor 4" OR TITLE:"EP4 receptor" OR ABSTRACT:"EP4 receptor") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EP4 (PTGER4), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ep4.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ep4.json. Licence CC BY-NC 4.0.